FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016103128> ?p ?o ?g. }

• W2016103128 endingPage "45" @default.
• W2016103128 startingPage "39" @default.
• W2016103128 abstract "Purpose To investigate predictors for gastrointestinal (GI) and genitourinary (GU) acute toxicity after a short-course hypofractionated radiotherapy regimen for prostate cancer. Materials and Methods Three institutions included 102 patients with T1-T3N0M0 prostate cancer in a Phase II study. Patients were treated with 56 Gy in 16 fractions over 4 weeks. Acute toxicity was scored weekly during treatment and 1 and 2 months after treatment using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria extended with additional symptoms and the International Prostate Symptom Index (IPSS). Correlation with a number of clinical and dosimetric parameters was assessed by univariate and multivariate analyses. Results No Grade 3 or 4 GI side effects were observed. Grades 1 and 2 rectal GI toxicity occurred in 36%, and 38%, respectively. Corresponding figures for Grades 1 and 2 GU toxicity were 42% and 39%, respectively. Grade 3 or higher GU toxicity was detected in 4% of patients. In multivariate analysis, percent rectal volumes higher than 8% receiving doses ≥53 Gy (V53) were statistically correlated to Grade 2 acute rectal reaction (p = 0.006). For GU morbidity, only the IPSS pretreatment score was independently associated (p = 0.0036) with an increase in GU acute effects. Conclusions Acute GU and GI toxicity were comparable with other series. Our data show that increased incidence and intensity of acute toxicity is a transient effect related to shorter overall treatment time rather than a larger effect in biological equivalent dose with respect to a conventional fractionation regime. To investigate predictors for gastrointestinal (GI) and genitourinary (GU) acute toxicity after a short-course hypofractionated radiotherapy regimen for prostate cancer. Three institutions included 102 patients with T1-T3N0M0 prostate cancer in a Phase II study. Patients were treated with 56 Gy in 16 fractions over 4 weeks. Acute toxicity was scored weekly during treatment and 1 and 2 months after treatment using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria extended with additional symptoms and the International Prostate Symptom Index (IPSS). Correlation with a number of clinical and dosimetric parameters was assessed by univariate and multivariate analyses. No Grade 3 or 4 GI side effects were observed. Grades 1 and 2 rectal GI toxicity occurred in 36%, and 38%, respectively. Corresponding figures for Grades 1 and 2 GU toxicity were 42% and 39%, respectively. Grade 3 or higher GU toxicity was detected in 4% of patients. In multivariate analysis, percent rectal volumes higher than 8% receiving doses ≥53 Gy (V53) were statistically correlated to Grade 2 acute rectal reaction (p = 0.006). For GU morbidity, only the IPSS pretreatment score was independently associated (p = 0.0036) with an increase in GU acute effects. Acute GU and GI toxicity were comparable with other series. Our data show that increased incidence and intensity of acute toxicity is a transient effect related to shorter overall treatment time rather than a larger effect in biological equivalent dose with respect to a conventional fractionation regime." @default.
• W2016103128 created "2016-06-24" @default.
• W2016103128 creator A5024554584 @default.
• W2016103128 creator A5045794019 @default.
• W2016103128 creator A5055056736 @default.
• W2016103128 creator A5055629115 @default.
• W2016103128 creator A5076959334 @default.
• W2016103128 creator A5083197997 @default.
• W2016103128 creator A5088794618 @default.
• W2016103128 creator A5089554789 @default.
• W2016103128 date "2009-01-01" @default.
• W2016103128 modified "2023-09-27" @default.
• W2016103128 title "Clinical and Dosimetric Predictors of Acute Toxicity After a 4-Week Hypofractionated External Beam Radiotherapy Regimen for Prostate Cancer: Results From a Multicentric Prospective Trial" @default.
• W2016103128 cites W1975713117 @default.
• W2016103128 cites W1979914233 @default.
• W2016103128 cites W1990510898 @default.
• W2016103128 cites W1996809772 @default.
• W2016103128 cites W1997716779 @default.
• W2016103128 cites W2002612178 @default.
• W2016103128 cites W2011486966 @default.
• W2016103128 cites W2012023853 @default.
• W2016103128 cites W2018393095 @default.
• W2016103128 cites W2023801183 @default.
• W2016103128 cites W2031657014 @default.
• W2016103128 cites W2035509954 @default.
• W2016103128 cites W2039960040 @default.
• W2016103128 cites W2040501025 @default.
• W2016103128 cites W2043945205 @default.
• W2016103128 cites W2048415179 @default.
• W2016103128 cites W2050744051 @default.
• W2016103128 cites W2056643793 @default.
• W2016103128 cites W2071365490 @default.
• W2016103128 cites W2087128023 @default.
• W2016103128 cites W2095491901 @default.
• W2016103128 cites W2096568394 @default.
• W2016103128 cites W2097532477 @default.
• W2016103128 cites W2099288242 @default.
• W2016103128 cites W2104631398 @default.
• W2016103128 cites W2111523836 @default.
• W2016103128 cites W2114214906 @default.
• W2016103128 cites W2115675646 @default.
• W2016103128 cites W2130514725 @default.
• W2016103128 cites W2130574795 @default.
• W2016103128 cites W2132515845 @default.
• W2016103128 cites W2135238404 @default.
• W2016103128 cites W2149407830 @default.
• W2016103128 cites W2153674426 @default.
• W2016103128 cites W2160406420 @default.
• W2016103128 cites W267547074 @default.
• W2016103128 cites W2993539218 @default.
• W2016103128 cites W3174275285 @default.
• W2016103128 doi "https://doi.org/10.1016/j.ijrobp.2008.04.005" @default.
• W2016103128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18538488" @default.
• W2016103128 hasPublicationYear "2009" @default.
• W2016103128 type Work @default.
• W2016103128 sameAs 2016103128 @default.
• W2016103128 citedByCount "21" @default.
• W2016103128 countsByYear W20161031282012 @default.
• W2016103128 countsByYear W20161031282013 @default.
• W2016103128 countsByYear W20161031282014 @default.
• W2016103128 countsByYear W20161031282015 @default.
• W2016103128 countsByYear W20161031282016 @default.
• W2016103128 countsByYear W20161031282017 @default.
• W2016103128 countsByYear W20161031282018 @default.
• W2016103128 countsByYear W20161031282019 @default.
• W2016103128 crossrefType "journal-article" @default.
• W2016103128 hasAuthorship W2016103128A5024554584 @default.
• W2016103128 hasAuthorship W2016103128A5045794019 @default.
• W2016103128 hasAuthorship W2016103128A5055056736 @default.
• W2016103128 hasAuthorship W2016103128A5055629115 @default.
• W2016103128 hasAuthorship W2016103128A5076959334 @default.
• W2016103128 hasAuthorship W2016103128A5083197997 @default.
• W2016103128 hasAuthorship W2016103128A5088794618 @default.
• W2016103128 hasAuthorship W2016103128A5089554789 @default.
• W2016103128 hasConcept C116263406 @default.
• W2016103128 hasConcept C121608353 @default.
• W2016103128 hasConcept C126322002 @default.
• W2016103128 hasConcept C126894567 @default.
• W2016103128 hasConcept C143998085 @default.
• W2016103128 hasConcept C144301174 @default.
• W2016103128 hasConcept C155806632 @default.
• W2016103128 hasConcept C188816634 @default.
• W2016103128 hasConcept C2776235491 @default.
• W2016103128 hasConcept C2780192828 @default.
• W2016103128 hasConcept C2781413609 @default.
• W2016103128 hasConcept C29730261 @default.
• W2016103128 hasConcept C38180746 @default.
• W2016103128 hasConcept C509974204 @default.
• W2016103128 hasConcept C71924100 @default.
• W2016103128 hasConceptScore W2016103128C116263406 @default.
• W2016103128 hasConceptScore W2016103128C121608353 @default.
• W2016103128 hasConceptScore W2016103128C126322002 @default.
• W2016103128 hasConceptScore W2016103128C126894567 @default.
• W2016103128 hasConceptScore W2016103128C143998085 @default.
• W2016103128 hasConceptScore W2016103128C144301174 @default.
• W2016103128 hasConceptScore W2016103128C155806632 @default.
• W2016103128 hasConceptScore W2016103128C188816634 @default.
• W2016103128 hasConceptScore W2016103128C2776235491 @default.

• next